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RESUMO 
O manganês (Mn) é um metal de transição de coloração branco acinzentado 
com propriedades semelhantes ao ferro e com uma distribuição ubíqua no 
ambiente. É importante para a fabricação de aços e de entre variadas 
aplicações, destaca-se a utilização em fertilizantes, produtos farmacêuticos, 
suplementos para animais e na produção de pilhas. Biologicamente o Mn é um 
oligoelemento e é essencial para todas as formas de vida, com importantes 
funções a nível do desenvolvimento e metabolismo. Dentro dessas funções 
destacam-se o papel fundamental do Mn no metabolismo de aminoácidos, 
hidratos de carbono e lípidos e em processos de protecção contra o stress 
oxidativo, nomeadamente como co-factor de enzimas tais como a superóxido 
dismutase (SOD). Em condições normais, e a nível ambiental, o Mn entra no 
organismo humano principalmente através da ingestão de alimentos e através 
das vias respiratórias, sendo normalmente absorvido a partir do tracto intestinal 
possivelmente por difusão passiva e transporte activo. Os níveis de Mn no 
organismo são ainda mantidos constantes por mecanismos homeostáticos que 
regulam não só a sua absorção como a sua excreção. No sangue, o Mn 
encontra-se principalmente nos eritrócitos e em níveis mais elevados é possível 
encontrá-lo no fígado, pâncreas, rins e cérebro. A distribuição do Mn varia de 
acordo com os diferentes tecidos, acumulando-se principalmente em tecidos 
ricos em actividade mitocondrial. Contudo, populações expostas, quer 
ambientalmente (através da água, alimentos e ar), quer ocupacionalmente 
(operários de indústrias metalúrgicas e mineiros) a níveis elevados de Mn, 
estão sujeitas a uma potencial exposição crónica com consequências muito 
nefastas para a sua saúde, principalmente a nível neurológico.  
Manganismo é o nome dado à intoxicação crónica neurodegenerativa causada 
pelo Mn e apresenta sintomas muito semelhantes à doença de Parkinson. Esta 
doença caracteriza-se pela acumulação de Mn em certas estruturas cerebrais, 
especialmente no sistema extrapiramidal, danificando progressivamente os 
neurónios dopaminérgicos nos gânglios basais, em zonas como o globus 
pallidus, striatum e substantia nigra. O cérebro é assim considerado o órgão 
alvo onde o Mn desenvolve a sua neurotoxicidade. A capacidade de atravessar 
as células endoteliais da barreira hematoencefálica permite ao Mn atingir zonas 
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do sistema nervoso central e produzir os seus efeitos neurotóxicos, porém 
ainda não foram identificados os mecanismos exactos que permitem esse 
transporte.  
Apesar de muito estudado, o mecanismo pelo qual o Mn provoca a sua 
neurotoxicidade é pouco elucidativo. Um grande número de estudos indica o 
stress oxidativo como o principal factor de toxicidade do Mn, resultante de um 
aumento no número de espécies reactivas de oxigénio (ROS) intracelularmente 
e a consequente apoptose. Existem essencialmente dois mecanismos 
induzidos pelo Mn capazes de provocar stress oxidativo: oxidação da dopamina 
e acumulação de Mn na mitocôndria. No que respeita à oxidação da dopamina 
pensa-se que a sobreexposição ao Mn leva à alteração do sistema 
dopaminérgico e consequente degradação da dopamina, do seu precursor 
DOPA e de outras catecolaminas. Quanto à acumulação na mitocôndria, o Mn 
inibe a fosforilação oxidativa, interferindo com o metabolismo energético ao 
nível da glicólise e do ciclo do ácido cítrico. A interrupção das funções 
mitocondriais pode levar ao stress oxidativo e à consequente diminuição de 
mecanismos de defesa celular, nomeadamente à redução de antioxidantes 
como a glutationa (GSH), e posteriormente à deterioração do ADN mitocondrial 
por radicais livres.    
Na tentativa de prever e evitar os potenciais efeitos adversos a nível da saúde, 
o estudo de indicadores biológicos é fundamental para determinar os níveis de 
exposição ao Mn e para prever a potencial consequência na saúde. A procura 
de indicadores biológicos de exposição que reflictam os níveis de exposição de 
Mn a que as populações estão sujeitas tornou-se assim crucial no objectivo de 
controlar a neurotoxicidade do Mn. Diferentes biomarcadores de exposição têm 
sido usados, em vários estudos, com este intuito, no sentido de demonstrar que 
concentrações de Mn no sangue, cabelo, esmalte dos dentes e urina estão 
associadas com a exposição ao Mn, permitindo distinguir grupos expostos de 
não expostos. Contudo todos estes indicadores têm aspectos negativos que 
limitam o seu uso como indicadores biológicos de exposição absolutamente 
confiáveis. Dentro desses aspectos destaca-se principalmente a ausência de 
informação relativamente a exposições prévias ao Mn, uma vez que os dados 
oferecidos por estes indicadores se referem a exposições recentes.  
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Além destes indicadores biológicos de exposição, existem também os 
biomarcadores de efeito que têm como objectivo último reflectir as 
mudanças/efeitos na saúde como consequência da exposição ao Mn. Como 
exemplo destes biomarcadores temos a GSH que participa em variadas 
reacções celulares, destruindo radicais livres e outras ROS, através de 
reacções enzimáticas. O stress oxidativo, resultante da neurotoxicidade do Mn, 
tem vindo a evidenciar um decréscimo nos níveis de GSH nas células, o que 
chamou a atenção para o uso desta molécula como indicador biológico de 
efeito.  
Também as concentrações de prolactina no soro têm sido usadas como 
indicadores da síntese dopaminérgica. A dopamina funciona como uma 
inibidora da libertação e síntese da prolactina da glândula pituitária, 
nomeadamente dos lactoforos. Tendo em conta que a exposição ao Mn causa 
alterações dos níveis de dopamina no cérebro, a produção de prolactina é um 
possível indicador da toxicidade do Mn e consequentemente um provável 
biomarcador efeito, já testado em variados estudos com correlações positivas e 
negativas. 
Apesar das variações de níveis destes propostos biomarcadores de efeito é de 
realçar que o stress oxidativo, como provável responsável das alterações 
mencionadas, faz parte de uma enorme quantidade de condições patológicas e 
neurotóxicas, acabando estes indicadores por ser uma medida indirecta do 
stress oxidativo em vez de uma medida da actividade oxidante. 
Com o objectivo de encontrar um possível tratamento que reduza ou elimine os 
efeitos da exposição crónica do Mn na saúde humana, propusemo-nos 
conduzir um ensaio de toxicidade sub-aguda in vivo de forma a analisar a 
interferência e possíveis efeitos protectores do antioxidante ebselen (EBS) e do 
agente quelante ácido para-aminosalicílico (PAS) na toxicidade do Mn, usando 
diferentes biomarcadores. Neste ensaio in vivo, ratos Wistar foram expostos a 
doses de Mn (cloreto de manganês) e co-expostos a Mn mais EBS via injecção 
intraperitoneal e ainda co-expostos a Mn mais PAS via injecção subcutânea.  
Avaliando a exposição ao Mn, os níveis de Mn no sangue e no cérebro foram 
determinados e verificou-se um aumento significativo quando comparados com 
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o controlo (p<0.05), demonstrando neste caso serem biomarcadores de 
exposição bastante úteis. 
Para avaliar biomarcadores de efeito, os níveis de glutationa foram medidos no 
cérebro para determinar as consequências do stress oxidativo e foi observado 
uma diminuição significativa (p<0.05) nos ratos exposto a Mn, tal como 
observado noutros estudos in vitro e in vivo. Foram ainda determinadas as 
concentrações na urina de malonaldeído (MDA), um indicador da peroxidação 
lipídica, mas este não mostrou ser um biomarcador válido da toxicidade do Mn. 
Por outro lado, os níveis de prolactina no soro tiveram um aumento significativo 
(p<0.05) nos animais expostos ao Mn, o que demonstrou a capacidade da 
hormona prolactina em funcionar como indicador fidedigno da neurotoxicidade 
do Mn. 
Testes comportamentais e medições de peso também foram efectuados e foi 
observado um decréscimo significativo (p<0.05) na actividade motora e no 
peso ganho dos animais exposto ao Mn. 
No que diz respeito aos resultados da exposição ao Mn com os dois químicos 
seleccionados, na sua generalidade foi observado um efeito positivo e protector 
contra a toxicidade provocada pelo Mn, contra a acumulação de Mn no cérebro 
e níveis de Mn no sangue, destacando o PAS e o EBS como químicos a serem 
utilizados e investigados em estudos futuros.  
Por fim foi ainda observada uma correlação entre os níveis de Mn no cérebro e 
os níveis de prolactina no soro (r2=0,98) e também com os efeitos 
comportamentais (r2=0,87), mais uma vez realçando este biomarcadores como 
válidos e sólidos. 
 
 
 
 
 
 
Palavras-Chave: manganês; ensaios in vivo; biomarcadores; stress oxidativo; 
ácido para-aminosalicílico; ebselen; neurotoxicidade 
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ABSTRACT 
 
Manganese (Mn) is an essential metal in all forms of life; however chronic 
manganese exposure in workers may cause serious neurological problems, 
often leading to adverse health effects, namely manganism. Oxidative stress is 
one of the mechanisms of Mn-induced toxicity and is thought to occur by the 
generation of reactive oxygen species (ROS) which may eventually lead to cell 
death. These ROS can have their function inhibited by antioxidants because of 
their important ability to remove free radicals. The aim of this study was to 
analyze the interference and possible protective effects of the chemicals p-
aminosalicylic acid (PAS) and ebselen (EBS) on Mn toxicity, using different 
biological indicators. In a sub-acute in vivo assay there were rats exposed to Mn 
alone (MnCl2, 10mg/kg) and co-exposed to Mn plus EBS (15 mg/kg) via 
intraperitoneal (i.p.) injection and co-exposed to Mn plus PAS (120mg/kg) by 
subcutaneous (s.c) injection. 
Mn levels in blood and brain were measured, both with significant increase 
when compared to control (p<0.05). Glutathione (GSH) levels were measured in 
brain to assess the consequences of Mn on oxidative stress and it was seen a 
significant decrease in the Mn exposed rats (p<0.05). Malondyaldehyde (MDA), 
a lipid peroxidation indicator, failed to be a valuable biomarker of Mn toxicity 
while, on the other hand, serum prolactin levels have shown a significant 
increase in the Mn exposed animals (p<0.05). Furthermore, it was observed a 
decrease in body weight gain and locomotor activity in the Mn treated animals 
(p<0.05). In general, a positive and protective effect against Mn-induced 
toxicity, brain Mn accumulation and Mn levels in blood was observed in the co-
exposed rats, pointing out PAS and EBS as chemicals to be used and 
investigated in further studies. Finally, it was observed a correlation between 
Mn levels in brain and the prolactin levels in serum (r2=0.98) and also with the 
behavioral effects (r2=0.87). 
 
 
Keywords: manganese; in vivo assays; biomarkers; oxidative stress; para-
aminosalicylic acid; ebselen; 
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1. Introduction 
 
1.1. MANGANESE – HISTORY AND APPLICATIONS 
Manganese (Mn) is a metal component of many types of rocks and is widely 
distributed in nature. The name Mn has it first origin in a region called Magnesia 
(today modern Greece) where two black minerals were called magnes (derived from 
Latin) that means “magnet” as a consequence of the magnetic properties of 
pyrolusite, a Mn mineral. Long time before, back in the Paleolithic period, men 
already used Mn dioxide (MnO2) as a pigment for their cave paintings. Later, in 
Ancient Greece, the Spartans made their weapons with iron ore rich in Mn. It is 
remarkable that Mn has also long been related to glass-making because the 
Egyptians and the Romans used Mn ore either to decolorize glass or to give it color 
and it has been used for this purpose until modern times since then. In the 17th 
Century, more precisely in 1771, Mn was first recognized by Carl-Wilhelm Scheele 
(a Swedish chemist) as an element and three years later, in 1774, isolated by one 
of his colleagues, Johan Gottlieb Gahn, by reduction of the dioxide with carbon. In 
the 19th Century occurred the major progresses in the use of Mn, especially in the 
steel industry, which lead nowadays to the development of an abundant number of 
metallurgical/chemicals processes and applications. 
As a free element, Mn is a metal with important industrial metal alloy uses, being 
used in the production of aluminum, copper and zinc but mainly, and most 
importantly, in steel production to improve rolling and forging qualities, hardness, 
stiffness, strength, toughness and wear resistance. Concerning non-metallurgical 
processes, it may also be used in the form of MnO2 as a depolarizer in dry-cell 
batteries and as an oxidizing agent in the chemical industry. Many Mn compounds 
are even used in fertilizers, animal feeds, pharmaceutical products, dyes, paint 
dryers, catalysts, and wood preservatives. As methylcyclopentadienyl Mn 
tricarbonyl (MMT), an organic Mn compound, Mn is used as an octane enhancer, 
anti-knock agent or smoke inhibitor in some unleaded gasoline [1]. This application 
appears to be important from an environmental point of view because it allows lead 
In vivo assays to study the interference of chemoprotectors on manganese neurotoxicity 
 
2 
 
to be replaced but it is also increasing Mn environmental levels, increasing the risk 
of exposure by inhalation to the populations, especially in urban areas [2]. 
 
1.2. PHYSICAL AND CHEMICAL PROPERTIES 
Mn has an atomic number of 25 and is an element of the Group VII of the Periodic 
Table being one of the transition metals. Because of it electron configuration Mn 
exists in a variety of oxidation states from -3 to +7, being +2, +3, and +7 the most 
common ones. The most stable oxidation state for Mn is +2 and it is in this state 
that we find the better known Mn (II) compounds, such as Mn sulfate (MnSO4) and 
MnCl2 (fig. 1). Pure Mn is silver-colored (fig. 2) and does not occur naturally, being 
combined with other substances such as iron, oxygen, sulfur, or chlorine. Mn exists 
in four allotropic forms which have different physical and chemical properties. The 
element changes from one form to another as the temperature rises. The melting 
point of Mn is 1,245°C (2,273°F) and its boiling point is about 2,100°C (3,800°F) 
while its density is 7.47g/cm3. The form that exists from room temperature up to 
about 700°C (1,300°F) is the most common form.  
 
 
 
                             
 
 
 
 
 
  Fig. 1 - Manganese chloride (MnCl2).                                        Fig. 2 - Pure manganese.                            
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1.3. SOURCES AND ROUTES AND OF EXPOSURE TO MN 
As one of the most abundant elements in the earth's crust Mn has a ubiquitous 
distribution in the environment being part of soils, sediments, rocks, water, and 
biological materials. It is considered to be the twelfth most abundant element and 
the fifth most abundant metal [3], [4]. Oxides, carbonates and silicates are the most 
important Mn-containing minerals and it also occurs in most iron ores. Its content in 
coal ranges from 6 µg/g to 100 µg/g and is present in crude oil, but at substantially 
lower concentrations [5]. Mn can enter the atmosphere by natural and 
anthropogenic processes, which include the suspension of road dusts by vehicles 
and wind erosion and the suspension of soils, particularly in agricultural, 
construction and quarrying activities [4]. However, the major sources of man-made 
environmental pollution by Mn come from the manufacture of alloys, steel, and iron 
products. Moreover, mining operations, the production and use of fertilizers and 
fungicides, and the production of synthetic Mn oxide and dry-cell batteries are also 
included in other sources. Coarse particles of Mn tend to settle out near sources of 
pollution, but fine particulate Mn can be distributed very widely [4]. The combustion 
of fossil fuels, containing MMT, can also release Mn into ambient air because MMT 
itself is rapidly photo degraded to inorganic Mn in sunlight, with an estimated half-
time of 10–15 seconds [6]. Regarding environmental sources and pathways of 
exposure, dietary intake of Mn generally dominates other routes of Mn exposure. 
Water and food Mn concentrations and rate of absorption may have a wide range of 
values, depending on several factors, including age [7], iron status [8], other 
nutrients in the diet [9], individual differences [10] and the kind of Mn compound 
[11]. Typically, about 3–8% of an ingested dose is absorbed and in general, Mn 
intakes are 0.1–24 µg/day for water and 2–8 mg/day for food. 
 
1.3.1. WATER 
 
Mn may be present in fresh water in both soluble and suspended forms. 
Concentrations of Mn in fresh water may vary, although drinking-water generally 
contains less than 100 µg/l [16]. In 100 of the largest cities in the United States, 
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97% of the surveyed public water supplies contained concentrations below 100 µg/l 
[6]. High Mn concentrations reaching several mg/l have been found in water 
draining mineralized areas and in water contaminated by industrial discharges. In 
open seawater a range concentration of Mn from 0.4 to 10 µg/l was also reported 
[6]. Further evidence of environmental exposure to high levels of Mn through 
exposure to contaminated water has been reported. Concentrations of trace 
elements measured in borehole, well and river water samples and urine samples 
from mine workers and non-mine workers in Tarkwa, a historic mining town in 
Ghana, were compared with tap water and urine samples from non-mine workers in 
Accra [17]. There was a significant increase in urine Mn concentration of both mine 
and non-mine workers in Tarkwa compared with that of workers in Accra. The 
presence of high levels of Mn has also been reported in bottled mineral waters [18]. 
 
1.3.2. FOOD 
 
Food generally constitutes a generous source of Mn intake for humans, but the 
concentrations vary depending of the type of food. The highest concentrations are 
found in certain foods of plant origin, especially wheat and rice, with concentrations 
between 10 mg/kg and 100 mg/kg. High concentrations of Mn have also been found 
in tea leaves. In a study performed in Canada, it was estimated that, the principal 
source of Mn via food came from cereals (54%) and potatoes (14%); meat, fish and 
poultry provided only 2% of Mn intake [19]. Other studies point out that dietary Mn 
intakes range from 1–2 mg/day in bland hospital diets to around 18 mg/day for diets 
consisting predominantly of vegetables, nuts and seeds [20]. In most human 
studies, the average daily intake of Mn by an adult has been reported to be between 
2 and 9 mg/day. Regarding the children aged 3-5 years and 9-13 years, the 
average daily intake is, respectively, 1.4 mg/day and 2.18 mg/day [21]. Bottle-fed 
and breastfed infants have very low daily intakes because of the low concentrations 
of Mn in both breast-milk and cow’s milk [22]. 
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1.3.3. AIR 
 
Mn can be found in measurable quantities in almost all air samples. Particle size is 
very important concerning the respiratory uptake of Mn by inhalation, with fine 
particles being small enough to reach the alveoli and be absorbed into the 
bloodstream. The water solubility of a Mn compound appears to affect the time 
course of respiratory tract absorption [12], but not necessarily the amount ultimately 
absorbed [13]. Some studies have indicated an extra-thoracic deposition as another 
possible route of exposure, stating that neurotoxic metals such as aluminium and 
Mn can be directly transported to the brain via nasal olfactory pathways [14], [15] . 
Annual average levels in ambient air in unpolluted urban and rural areas vary from 
0.01 to 0.07 µg/m3. However, in areas associated with Mn industry, annual 
averages may be higher than 0.5 µg/m3, and have occasionally exceeded 8 µg/m3. 
Mn is also present in MMT, an octane-enhancing fuel additive used in unleaded 
automobile gasoline. Because of MMT high instability in light and very fast 
degradation in air, there’s a great concern about the exposure to its combustion 
products. A study in 2007 showed that Mn exposure, in the form of MMT in car 
exhaust fumes from Canadian cities was associated with an increased of Parkinson 
disease (PD)-like symptoms [24]. Using various environmental modeling 
approaches, it was estimated that air levels of Mn in most urban areas in the United 
States would increase less than 0.02 µg/m3 if MMT were used in all unleaded 
gasoline [25]. Signs of adverse effects may occur at Mn concentrations in air 
ranging from 2 to 5 mg/m3. 
 
1.3.4. OCCUPATIONAL EXPOSURE 
 
Chronic Mn intoxication is a hazard in the mining and processing of Mn ores, in the 
Mn alloy, dry-cell battery industries, and in welding. Mn fumes are produced during 
metallurgical operations and several types of welding operations, and the exposure 
can vary considerably depending on the amount of Mn in the welding wire, rods, flux 
and base metal. Confined space welding can significantly increase the exposure to 
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Mn fumes or Mn-containing dusts, mainly by inhalation [23] and direct absorption of 
Mn in brain. A major part of Mn present in the air in work areas appear in the form of 
oxides. Values ranging from 0.8 to 17 mg/m3 have been reported in ore-crushing 
plants. In steel plants, air concentrations are generally in the range of 0.1-5 mg/m3, 
only rarely exceeding 10 mg/m3. However, welders may be exposed to air 
concentrations exceeding 10 mg/m3 which is a huge quantity considering the World 
Health Organization (WHO) recommendation of 0.3 mg/m3 for inhaled Mn particles 
as a occupational exposure limit (OEL) [108]. 
 
 
1.4. MN EXPOSURE AND HEALTH EFFECTS 
 
Individual susceptibility to the adverse effects of Mn varies considerably with 
exposure duration, genetic factors and the type of Mn compound.  The early life 
exposure to excessive Mn has been associated with neurodevelopment deficits 
such as intellectual performance shortcomings and behavioral changes. Various 
epidemiological studies of workers exposed to Mn at average levels below 5 mg/m3 
have shown neurobehavioral, reproductive, respiratory and neurotoxic effects, both 
by objective testing methods and by workers' self-reported symptoms on 
questionnaires [26], [27], [28], [29].  
 
1.4.1. RESPIRATORY EFFECTS 
 
At low to moderate occupational Mn exposure levels, it was recognized that self-
reported symptoms of respiratory tract illnesses did exist. The respiratory effect of 
occupational Mn exposure may be due to the inhalation of particulate matter, but in 
a recent study, where it was seen a low respiratory performance in Mn welders, it 
has been suggested to be linked to subclinical neurotoxic symptoms [35]. Also, 
recently, an isolated and rare case of Mn-induced occupational asthma has been 
reported, where an employee who worked 20 years in a train factory and has been 
exposed to aerosols including Mn, developed occupational asthma [36]. 
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1.4.2. REPRODUCTIVE EFFECTS 
 
Regarding reproductive effects, it has been noticed a smaller number of children 
born to Mn-exposed workers compared to matched controls, and various self-
reported symptoms of sexual dysfunction. In a 2007 study with 200 males’ patients, 
a decline of fertility has been related to Mn exposure, leading the authors to suggest 
that Mn adversely affects both sperm motility and concentration [33]. Furthermore, 
an evaluation, carried out in 542 healthy pregnant women’s, determining the 
importance of Mn levels in maternal and umbilical cord blood on intrauterine growth 
retardation revealed a significant correlation between both [34]. 
 
1.4.3. NEUROBEHAVIORAL EFFECTS 
 
In terms of neurobehavioral effects, disturbances in the control of hand movements 
like tremors and slower finger-tapping speed have been commonly reflected. A 
study comparing 96 welders, exposed to Mn in welding fume, with 96 age matched 
controls revealed that welders exposed to the high Mn concentrations had 
statistically poorer finger-tapping test score than controls [30], [31]. A review of 
occupational, environmental and childhood exposure studies greatly reinforced the 
neurobehavioral effects of Mn, inducing the authors to propose that a test battery of 
motor function, response speed, cognitive functions, intellectual abilities, mood and 
symptom questionnaires tests should be included in future studies as a core battery 
to determine any Mn effect [32]. 
 
1.4.4. MANGANISM 
 
Chronic Mn inhalation leads to a characteristic neurotoxicity known as manganism 
with strong similarities to PD. John Couper was the first to report neurological 
effects associated with exposure to Mn in the scientific literature in 1837, when he 
described muscle weakness, limb tremor, whispering speech, salivation, and a bent 
posture in five men working in a Mn ore crushing plant in France [46]. He called this 
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collection of symptoms “manganese crusher’s disease”, which was later, called as 
“manganism”. Manganism is characterized by diminished motor skills (e.g. dystonia, 
awkward gait, tremors, speech difficulties, impaired hand-eye coordination) and 
may include psychological disturbances. 
Despite their similarities, the symptoms of manganism and PD differ somehow [37], 
[38]. Both manganism and PD have in common bradykinesia and widespread 
rigidity, but tremors are less frequent in manganism while dystonia is more frequent. 
Manganism can also be distinguished from Parkinson’s by a propensity to fall 
backward, failure to achieve a sustained therapeutic response to levodopa, and 
failure to detect a reduction in fluorodopa uptake by positron emission tomography 
[38]. In Parkinsonism, the damage seems to be restricted and affecting mainly de 
dopamine neurons in the substantia nigra pars compacta and in manganism the 
damage involves other parts of the basal ganglia, appearing to be more widespread 
[39], [40]. In a proposed model of PD, it was shown decreased motor performance 
resulting akinesia, postural instability and tremors. Besides all these changes being 
considered a sign of PD, the role of dopamine in the damaging process was not yet 
completely clarified [41], which solidifies the view that, despite symptoms of PD and 
manganism have similarities, there are distinct pathophysiological differences 
between the two conditions [42]. Mn accumulates in certain brain structures, 
especially the extrapyramidal system, and structures rich in dopaminergic neurons 
also show a heightened sensitivity to Mn toxicity. Brain imaging studies have also 
recently begun to provide additional insight into the neuropathology of Mn toxicity. 
The use of T1-weighted magnetic resonance imaging (MRI) techniques has shown 
that in nonhuman primates and in patients, given high doses of Mn, high signal 
intensities of brain Mn concentrations were localized in the striatum, globus pallidus, 
and substantia nigra [43], [44], [45] (fig. 3). 
The chelation therapy has been used for treatment of severe cases of Mn 
intoxication but lack of effective treatment has been an enormous barrier in clinical 
management of occupational Mn intoxication [47]. Ethylene Diamine Tetraacetic 
Acid (EDTA) treatment has been shown to increase Mn excretion in urine and 
decrease Mn concentrations in blood, removing mainly the extracellular Mn ions 
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with promising clinical results [48]. Tough, the absence of symptomatic clinical 
improvement with this treatment comes from the inability of EDTA to repair the 
damaged neurons which is thought to be due to its four highly water soluble 
carboxyl groups, which prevent the molecule from effectively crossing the blood–
brain barrier (BBB) [49].  
 
 
                                                     Fig. 3 - Brain zones affected by Mn [210]. 
 
2. MN TOXICOKINETICS 
 
Mn is an essential nutrient not only involved in amino acid, cholesterol, and 
carbohydrate metabolism but it is also required in a number of metalloenzymes, 
which includes arginase, glutamine synthetase, phosphoenolpyruvate 
decarboxylase, and superoxide dismutase (SOD) [50]. Environmental Mn enters the 
human body mainly by the oral and inhalation pathways while normally the 
absorption through the skin is insignificant [51], [52]. Levels of Mn in organs are 
maintained at stable levels by homeostatic mechanisms involving regulation of 
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uptake and excretion [53]. However, Mn homeostasis is not maintained in newborn 
infants, neither is it known how long it takes for it to develop [50]. Several 
experimental studies have demonstrated that Mn levels in tissue are well regulated 
when ingested. Mn is normally absorbed from the intestinal tract as part of the diet 
and it is estimated that 2 to 5% of ingested Mn is absorbed by the human adult 
organism [54]. Despite Mn absorption mechanisms aren’t still fully clear, it appears 
to be absorbed from the gastrointestinal (GI) tract by passive diffusion and active 
transport [55], largely in the divalent form, with approximately 80% of absorbed Mn 
subsequently bound in plasma to s1-globulin and albumin [56]. Furthermore, Mn 
uptake from the GI tract is reduced in the presence of high levels of Mn in the diet 
and also is thought to be enhanced by iron deficiency, not only in the GI tract but 
also in the lungs and nose [57], [58]. From another point of view, at low Mn intake 
levels, Mn bioavailability is enhanced by ascorbic acid and inhibited by some dietary 
fiber sources [59]. 
All the Mn-protein complexes are efficiently removed from the blood by the liver that 
plays a key role in maintaining normal organ Mn concentrations. Then they are 
returned to the gut, mainly through the bile for elimination and in lesser amounts via 
urine [60], regulating the percentage of ingested Mn retained by the body and 
limiting the increase in systemic Mn tissue concentrations. A small fraction of Mn in 
the intestine is still reabsorbed, establishing an enterohepatic circulation [61]. Both 
the rate of excretion and the amount of Mn eliminated are influenced, as seen 
above, by the amount of Mn intake, the iron status in the body, the influence of 
other dietary components and unique genetic characteristics. In the blood, unbound 
Mn was thought to be converted by ceruloplasmin, an oxidase protein that is 
postulated to be involved in the mediation of Fe and Mn oxidation, to the trivalent 
cation which is then bound by transferrin (Tf). Tf-Mn complexes are removed with 
reduced efficiency by the liver and thereby circulate throughout the body as a result 
of surviving the first pass elimination [62]. However, recent results showed that 
ceruloplasmin is not involved in the loading of Mn on to plasma Tf but it was shown 
to affect retention of Mn in the blood, and consequently tissue distribution of Mn 
[63]. 
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Mn distribution varies greatly accordingly to the different tissues. On a normal 
accumulation basis, bones contain the highest amount [64] followed by the liver, 
skeletal muscle, connective tissue and intestine. After an i.p injection, Mn is rapidly 
distributed, accumulating in tissues that are rich in mitochondria and endoplasmic 
reticulum [65] and the highest Mn concentrations can be found in tissues with high 
energy demands, such as the brain, and other metabolic organs like the liver, 
pancreas and kidneys [66]. 
 
 
3. THE BRAIN: A TARGET ORGAN FOR MN TOXICITY 
 
3.1. BLOOD – BRAIN BARRIER 
 
The concept of BBB was first introduced by Paul Ehrlich.  He found that intravenous 
injection of dyes into the bloodstream stained all the tissues in most organs except 
the brain [67]. Ehrlich believed that the dye did not stain the brain because the brain 
lacked the ability to bind it but some years later, his colleague, Edwin Goldmann 
rejected this hypothesis by showing that the same dye, when injected into the 
cerebrospinal fluid (CSF), did indeed stain the brain [68]. This experiment, besides 
demonstrating the presence of a BBB, also showed that there was no permeability 
barrier between CSF and the brain. Nowadays, we know that the BBB acts both as 
a physical barrier and as a system of cellular transport mechanisms, protecting the 
nervous system from potential harmful toxicants by restricting their entrance from 
the blood. It is formed by a complex organization of cerebral endothelial cells of 
blood capillaries, pericytes and their basal lamina, which are surrounded and 
supported by astrocytes and perivascular macrophages (Fig. 4). These cerebral 
endothelial cells, in contrast to endothelial cells in many other organs, have the 
presence of continuous tight and adherens junctions that seal together the margins 
between cells [69]. Furthermore, brain capillary endothelial cells contain no direct 
transendothelial passageways such as fenestrations or channels [70] which help 
maintaining the restrictive properties of the BBB. 
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Lipid-soluble solutes can cross the BBB because they are able to penetrate the lipid 
bilayers of the endothelial cells by facilitated diffusion and, in addition, selected 
polar solutes can cross the BBB because specific, carrier-mediated transport 
systems are present in the endothelial cell membranes. Thus, carrier-mediated 
transport is saturable because the number of binding site is limited. These specific 
transport systems facilitate the uptake of important nutrients, hormones and active 
pumps that help regulate the concentrations of ions and metabolites in brain. Many 
of these BBB properties are likely to be under regulation either by neurotransmitters 
and hormones released in the brain or by those present in the systemic circulation. 
 
                                   Fig. 4 - The blood brain barrier [211]. 
                                   
3.2. MN PATHWAYS INTO THE BRAIN 
 
Mn exposure, via the pulmonary route, leads to more rapid absorption with higher 
efficiency and with greater transfer to the brain compared with other routes [85], 
[86]. Inhaled Mn, that enters the bloodstream, passes first to the brain before being 
processed by the liver. Experimental studies using radiolabelled Mn indicate that the 
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metal is eliminated more slowly from the brain than from most other organs or the 
body as a whole [71], [72], [73]. Mn can take three different pathways to enter the 
brain: via the capillary endothelial cells of the BBB, via the choroid plexus of the 
blood-CSF barrier and finally, directly via the olfactory nerve from the nasal cavity 
[74], [75]. While at normal plasma levels, Mn enters the brain mainly across the 
capillary epithelium but at elevated levels of Mn in blood, transport across the 
choroids plexus becomes more prominent [76]. The regulation of substrate entry 
into the brain via the choroids plexus differs from the one at the BBB because 
capillaries in the choroids plexus are fenestrated and the substances are taken by 
choroids plexus epithelium which then secretes CSF and eventually the neuronal 
uptake of substances keeps going via the cells of ependyma. Regarding the 
entrance via the olfactory nerves, neither pulmonary nor GI absorption is required 
for this route of exposure, and the BBB is bypassed. In a 2006 study it was found 
evidence that Mn ultrafine particles may be absorbed across the nasal epithelium 
and transported directly to the brain in rats [77]. 
Depending on its ability to cross the BBB, Mn may reach areas of the central 
nervous system and produce characteristic neurotoxic effects. In the brain, Tf 
receptors localized on the surface of the cerebral capillaries may mediate the 
uptake of Mn in regions such as the nucleus accumbens and caudate putamen. 
From these regions, it is thought that Mn circulates by neuronal transport to the 
pallidum, thalamic nuclei, and substantia nigra [78]. The identified potential 
mechanisms for Mn uptake across the BBB include: facilitated diffusion, active 
transport, divalent metal transport 1 (DMT-1) mediated transport (fig. 5), ZIP8-
mediated transport and Tf-dependant transport (fig. 5), although the predominant 
mechanism has not yet been discovered [79]. The DMT1-mediated transport is 
known to be needed in the olfactory uptake of Mn but it is likely not important as 
others for Mn transfer across the BBB [80]. There are also recent evidences of the 
function that ZIP transporter proteins, members of the solute-carrier-39 (SLC39) 
metal-transporter family [81], have in Mn transport, although it is still not clearly 
understood if these proteins are functional at the BBB. In plants, several ZIP 
proteins have been implicated in divalent metal transport, including zinc (Zn), Fe 
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and Mn. An in vitro study in mouse fetal fibroblast cultures established that ZIP8 has 
a high affinity for Mn [82]; however, the ability of this protein to transport a particular 
cation is not sufficient to conclude if it is physiologically relevant in an in vivo study 
[83]. Regarding the Tf-dependant transport it was thought that, because Mn2+ can 
be oxidized to Mn3+, it would bind to Tf and then to a Tf receptor on the cell surface, 
similar to Fe transport. However, some experiments found that coadministration of 
Mn2+ with Tf either lowered or did not change total brain Mn uptake [86], [87], [88]. 
This clearly suggests that some other transport system is responsible for brain Mn 
uptake. Recently, inhibition of the dopamine transporter (DAT) by the specific DAT 
inhibitor GBR12909 has shown to decrease Mn accumulation in striatal 
synaptosomes [90], nevertheless, other studies have suggested that DAT does not 
play a role in Mn cytotoxicity in dopaminergic cells [91]. There is also some 
evidence that low molecular weight species, such as Mn-citrate, may pass directly 
across the BBB without need of a transport facilitator [97]. 
These mentioned mechanisms are thought to apply generally to the transport of 
Mn across the BBB of adults, however, in the fetus and neonate, the BBB is 
characterized by having greater permeability to many substances, including Mn, 
and a different distribution of molecular transporters [89].  
 
 
 
Fig 5. Transport mechanisms potential responsible for the uptake of Mn. Tf transferrin; TfR 
transferrin receptor; DMT1 divalent metal transporter [212]. 
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4. NEUROTOXICITY MECHANISMS: THE ROLE OF OXIDATIVE STRESS 
 
There are numerous theories about potential mechanisms of Mn-induced 
neurotoxicity [92]. Oxidative stress is one of those theories. Mn has been 
hypothesized to produce oxidative stress in the CNS by various pathways after the 
observation of changes in biomarkers of oxidative stress upon exposure to high 
levels of Mn. There are two essential mechanisms capable of leading to a Mn-
induced oxidative stress. The first one is dopamine oxidation by Mn, especially 
since Mn exposure in non-human primate and rodent studies, leads to alteration of 
the dopaminergic system, often observed as degeneration of dopamine nerve 
terminals, reduced dopamine content or receptor binding in the brain, particular at 
dopamine-rich brain regions such as the basal ganglia [93], [94], [95]. The striatum 
is a major recipient structure of neuronal efferents in the basal ganglia receiving 
dopaminergic inputs from substantia nigra and projecting them to the internal 
segment of the globus pallidus [99]. Therefore the nigrostriatal dopamine neurons 
appear to be particularly sensitive to Mn-induced neurotoxicity, shown by reductions 
in striatal dopamine levels in some studies [100]. It is known that Mn2+ catalyzes 
Fenton-type reactions (Fig. 6), generating hydroxyl radical and triggering proteolytic 
degradation and can also give rise to the trivalent form (Mn3+). In biological 
systems, Mn3+ appears to be responsible for Mn pro-oxidant properties, possibly 
because it takes part in the Fenton-type reactions [98]. In vitro studies trying to 
mimic conditions in the brain have shown that Mn3+, but not Mn2+ (both as 
pyrophosphate), oxidizes dopamine, its precursor dihydroxyphenylalanine (DOPA), 
norepinephrine, and epinephrine to quinones and other products, with reduction of 
Mn3+ to Mn(OH)2 [96]. Polymerization of these catecholamines derived quinones to 
form neuromelanin, from which the substantia nigra derives its name, is an auto-
oxidative process that enhances oxidation of Mn2+ to Mn3+, increasing cellular 
oxidative stress.  
The second mechanism is trough Mn accumulation in the mitochondria. Within brain 
structures, and after exposure, Mn is found dominantly in mitochondria where it 
inhibits oxidative phosphorylation and disrupts mitochondrial function [101], 
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interfering with energy metabolism at the level of glycolysis and the citric acid cycle, 
as implied by in vivo and in vitro evidence [102], [103], [104]. The mitochondrial 
dysfunctional effects of Mn may result in oxidative stress to cellular defense 
mechanisms (e.g. GSH) and, afterwards, free radical damage to mitochondrial 
DNA. Mn3+ can also promote the formation of ROS [98] (Fig. 7) which can lead to 
oxidative stress, which in turn can cause apoptosis of neurons of the rat brain [105]. 
This increase in ROS is initially generated by small initial amounts of oxygen self-
propagating, via damage to the electron transport chain in mitochondria. When 
proteins or quinones that participate in transfer of electrons are damaged, the chain 
begins to donate electrons directly to molecular oxygen, thereby creating the highly 
reactive superoxide radical (O2
-) [106]. This is called an electron leak, potentially 
damaging mitochondria directly or through the effects of secondary oxidants like the 
superoxide, hydrogen peroxide (H2O2) or peroxynitrite (ONOO
-). Moreover, the 
produced superoxide may catalyze the transition shift of Mn2+ to Mn3+ through a set 
of reactions similar to those mediated by SOD and thus leading to the increased 
oxidant capacity of Mn [107]. 
 
 
 
 
 
                                                                                            Fig. 7 - Formation and inactivation of ROS. 
 
Fig. 6 – Fenton Reaction. 
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5. CHEMOPROTECTORS: TWO PROBABLE TREATMENTS  
 
5.1. EBSELEN 
 
Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one]; (Fig. x) is a seleno-organic 
drug that has been extensively studied during the last decade. Unlike many 
inorganic and aliphatic selenium compounds, ebselen is not toxic to mammals 
[109]. The most important characteristic of ebselen pharmacological profile appears 
to be due to its unique mode of action as an antioxidant. In contrast with other 
antioxidants, although generally considered to be one, ebselen is not a free radical 
scavenger per se. The main neuroprotective mechanism of ebselen has been linked 
to its reduction of H2O2 and lipid hydroperoxides via its interaction with the 
thioredoxin system [110]. Thus, the particular interest in this drug is that ebselen 
mimics GSH peroxidase (GPx) activities in particular that of phospholipid 
hydroperoxide GPx [111]. Like these enzymes, ebselen combined with GSH or N-
acetyl-cysteine (NAC) acts through a selenium core to eliminate hydroperoxides 
and lipoperoxides. Ebselen is an excellent direct substrate for mammalian 
thioredoxin reductase, reacting quickly with H2O2 to form H2O, and the ebselen 
selenic acid spontaneously releases another molecule of H2O to regenerate 
ebselen. However, ebselen also produce several chemical reactions not restricted 
to the GPx reaction. In vitro studies have revealed that ebselen induced the 
inhibition of a number of enzymes involved in inflammation and capable of 
producing free radicals, which includes inducible nitric oxide synthase (NOs) [112], 
5- and 15-lipoxygenases [113], NADPH oxidase [114], protein kinase nitric oxide 
synthase C, and H+/K+-ATPase [111]. Moreover, ebselen has been shown to protect 
mitochondria, a well known source of free radicals, from lipid peroxidation through 
its direct antioxidant properties [115] In addition to its antioxidant and anti-
inflammatory properties, the BBB permeability to ebselen and a rapid absorption 
following oral administration [110], [116] makes ebselen a very useful chemical in 
the treatment of different diseases. 
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5.2. PARA-AMINOSALICYLIC ACID
 
Para-aminosalicylic acid (PAS
acid], also called PASER, Paramycin, or Parasal, has been used as an anti
tuberculosis drug since the early 1950s. The chemical structure of PAS consists 
carboxyl, hydroxyl and amine groups, which provide promising chelating moieties 
for metals. The exact me
effectiveness against Mn toxicity may be explained by two putative mechanisms. 
First, Mn3+ can form a stable complex with hard donor atoms such as oxygen 
donors in PAS structure. In contrast, the Mn
and thus prefers relatively softer donors such as nitrogen, which is also present in 
PAS structure [117]. Consequently, Mn
two most common valence
Whether PAS chelates physiological Mn or excessive Mn is unknown. 
pioneering study in India, PAS was shown to remove 52% of Mn from liver and 
testis in Mn-exposed rats
Mn concentration by 26% 
treatment increased Mn excretion in feces by 140% in Mn
24 h sample collection 
concentrations by PAS treatment i
PAS was only for a few days. Recent studies have reported that such a short period 
of PAS treatment is unlikely to produce any therapeutic outcomes, being needed 
higher and sustainable doses
Second, from the chemistry point of view, the salicylate moiety in PAS structure 
possesses an anti-inflammatory effect and recent studies have suggested that 
 
Fig. 8 - Chemical Structure of Ebselen. 
 
), [4-amino-2-hydroxybenzoic acid, 4
chanism by which PAS chelates Mn is unclear and its 
2+ cation has a lower charge density 
-PAS complexes may be formed and those 
 states of Mn ions may be easily remo
 [118] and in a similar animal model, PAS reduced brain 
[119]. The same investigators also showed that PAS 
-exposed rabbits during a 
[120]. Another study found no reduction of tissue Mn 
n a mouse model [121] but 
 to observe a positive effect [49]. 
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sodium salicylic acid, may have neuroprotective benefit, because the inflammatory 
processes have been shown to play a role in the pathogenesis of 
neurodegenerative diseases such as Alzheimer disease and 
Therefore, chemicals such as PAS may facilitate regulation of neurotransmitters, 
suppress nitric oxide (NO) 
and neuroglia. Nevertheless, the chelating chemistry between PAS, Mn and other 
metals need to be further investigated, alongside with the hypothetical 
neuroprotective effects of
damage.  
 
6. BIOMARKERS 
 
 
A biomarker is any substance or metabolite that may be measured in the body to 
estimate external exposure levels or to predict the potential for adverse health 
effects or disease. There are three main classes of biomarkers: biomarkers of 
exposure, effect, and susceptibility. Although there are studies proposing that some 
genes may serve as susceptibility biomarkers for Mn neurotoxicity, there are not 
any validated biomarkers of susceptibility
 
6.1. BIOMARKERS OF 
 
The search for a suitable biomarker of early Mn exposure has become fundamental 
in the clinical investigation and control of Mn neurotoxicity. Ideally, biological 
markers of exposure should reflect an 
and its usefulness depends on how accurately it reflects the environmental 
synthesis, and protect against oxidative stress in neurons 
 PAS in treatment of Mn-induced 
 
     Fig. 9 - Chemical structure of PAS.  
 [133]. 
EXPOSURE 
integration of the internal 
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exposure level, which typically requires studies to validate the biomarker. Various 
studies have used a few different biomarkers of exposure and have reported that 
blood Mn [124], [125], hair [126], [127], tooth enamel [128], or urine [129], are 
associated with Mn exposure. However the association between the exposure 
biomarker and the occurring effects is very limited, reflecting the difficult challenge 
to identify and validate biomarkers for Mn exposure and effect. Studies have shown 
that the relationship between Mn dose and blood Mn level as a biomarker of 
exposure is uncertain, and seems dependent on the magnitude, duration, 
frequency, variability and latency of exposure [130]. In fact, some authors consider 
that Mn levels in blood poorly reflects the body burden of Mn in chronic exposure 
[131], being this assumption based on experimental studies showing that t1/2 of Mn 
in blood is about 2h [132]. Furthermore, blood Mn is not a good indicator of the 
amount of Mn absorbed shortly before sampling or occurring during the previous 
days, because it changes very little with inhalation exposure [133] and can also 
change as a result of dietary intake, which may influence the results of the study 
[134]. Despite these evidences, a consistently high level of blood Mn in any 
individual should always suggest recent exposure to Mn. Plasma Mn appears to be 
of little utility as a biomarker [130] and urine Mn is also unlikely to indicate Mn 
toxicity because Mn is primarily excreted in the bile, and only approximately 1% is 
excreted in urine [135], tough there are studies suggesting that urine Mn is a good 
indicator [129], [136]. Hair is also not a reliable indicator of exposure, as there is 
potential for external Mn exposures that may affect Mn levels in hair, limiting its use 
as an indicator of internal dose. The concentration of Mn in hair may also be 
affected by the degree of pigmentation [137].  It is noteworthy that most studies 
have failed in report a dose-response relationship between exposure levels and Mn 
in blood, urine and hair, further limiting the use of Mn biomarkers of exposure. 
 
6.2. BIOMARKERS OF EFFECT 
 
The biomarkers of effect reflect the changes/resulting health effects as a 
consequence of the exposure, with a significant correlation. Specific early 
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biomarkers of effect, such as subclinical neurobehavioral or neurological changes or 
MRI changes have not been established or validated for Mn although many studies 
have attempted to correlate biomarkers and neurological effects. 
 
6.2.1. PROLACTIN 
 
Prolactin (PRL) also known as luteotropic hormone (LTH) is a single-chain peptide 
hormone discovered by Dr. Henry Friesen, a Canadian endocrinologist, and is 
essentially associated with lactation because one of its effects is the stimulation of 
the mammary glands to produce milk. Most recently, there are several situations in 
which serum PRL concentrations are indicative of dopamine synthesis, linked to 
PD. Therefore, PRL production and secretion may be targets for Mn toxicity. Based 
on the fact that Mn exposure causes dopamine disturbances in brain [138], and that 
dopamine serves as an inhibitor to the release and synthesis of PRL from the 
endocrine portion of pituitary gland, more specifically from the lactotrophs [139], 
serum PRL has been used as a biomarker in non-occupational studies in which its 
serum levels correlate positively to blood Mn [139]. Furthermore, since Mn exposure 
may alter cerebral dopamine concentrations, serum PRL levels may increase which 
has in fact been found in workers exposed to Mn [141], [30], [142]. It has been also 
reported recently a positive relationship between concentrations of Mn in blood and 
PRL concentrations [140] suggesting that Mn levels in blood could be used to 
determine serum PRL levels. Nevertheless, some negative correlations have also 
been reported [26], [143].  
 
6.2.2. GSH 
 
Glutathione (L-g-glutamyl-L-cysteinylglycine) is a ubiquitous molecule that is 
produced in all organs and is the principal nonprotein thiol involved in the 
antioxidant cellular defense. It is a tripeptide composed of cysteine, glutamic acid 
and glycine, and its active group is represented by the thiol (–SH) of cysteine 
residue (Fig. 10). In cells, total GSH can be free or bound to proteins. Free GSH is 
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present mainly in its reduced form, which can be converted to the oxidized form 
during oxidative stress, and can be reverted to the reduced form by the action of the 
enzyme GSH reductase. The redox status depends on the relative amounts of the 
reduced and oxidized forms of glutathione (GSH/GSSG) and appears to be a critical 
determinant in the cell. GSH/GSSG is the most important redox couple and plays 
crucial roles in antioxidant defense, nutrient metabolism, and the regulation of 
pathways essential for whole body homeostasis. GSH participates in many cellular 
reactions where it can effectively scavenge free radicals and other ROS directly and 
indirectly through enzymatic reactions [144]. 
Over the past few years, a series of experiments have tried to examine several 
biomarkers of oxidative stress in the brain of Mn-exposed rats. In one of those 
studies, oxidative stress was indirectly assessed by measuring the levels of two 
important antioxidants, GSH and metallothionein (MT), as well as glutamine 
synthetase (GS) [145]. In the hypothalamus of rats, subchronic inhalation of Mn has 
been associated with a decrease in GSH and an increase in MT mRNA, while the 
olfactory bulb experienced an increase in GS [105]. Similarly, subchronic Mn 
inhalation by rhesus monkeys resulted in decreased tyrosine hydroxylase (TH), 
glutamate transporter-1, glutamate/aspartate transporter, and GS [146]. These may 
happen due to exposure to oxidative stress resulting in a less effective 
neurotransmitter synthesis, while increased MT mRNA in all the brain regions 
examined is a cellular response to enhance the effects of ROS. There is also 
evidence that Mn effect on GSH may be influenced by age and sex. A study has 
shown that total GSH levels significantly decreased in the olfactory bulb of young 
males, but increased in females. In the striatum, GSH levels were significantly 
decreased in females and old males but were largely unchanged in young males 
[147]. 
Despite the changes in various oxidative stress biomarkers in these studies they do 
not often reflect a consistent dose-dependence with Mn treatment. Oxidative stress 
is part of a broad range of neurotoxic and pathologic conditions and often is not a 
primary mechanism of injury. All of these biomarkers are indirect measurements of 
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7. OBJECTIVES 
 
The main objective was: 
 
• To study the interference of two chemoprotectors (PAS and EBS), in the Mn 
neurotoxicity using biomarkers of exposure and effect. 
 
To reach this objective we used an in vivo assay with rats repeatedly exposed to Mn 
alone and rats co-exposed to Mn plus EBS and Mn plus PAS, which allowed us to 
evaluate the following biomarkers: 
 
• Biomarkers of exposure - Mn levels in brain and blood 
 
• Biomarkers of effect - GSH, PRL, MDA and behavior assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo assays to study the interference of chemoprotectors on manganese neurotoxicity 
 
25 
 
 
8. MATERIALS AND METHODS 
 
 
8.1. ANIMALS 
 
 
Male Wistar rats (141-169g) were purchased from Charles River Laboratories ®, 
Barcelona. Upon arrival, the animals were housed in an independent room at 24 oC 
with temperature control, 12-h light/dark cycle and 50-70% humidity. It was provided 
free access to water and food, supplied as pellets adequate for normal growth, 
reproduction, and maintenance.  
The general condition of all rats was checked every day. All the animals were 
treated according to the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals” prepared by the National Academy of Sciences and published 
by the National Institutes of Health (United States of America) and according to the 
“Directive of the European Parliament and of the Council on the protection of 
animals used for scientific purposes” (European Union). 
 
 
8.2. IN VIVO ASSAYS 
 
 
According to normal procedure, all the animals were acclimatized for a period of 10 
days prior to experimentation and during this period, a 24 h urine sample was 
collected, body weight was measured and behavioral analysis were performed. 
Afterwards, rats were randomly distributed into 6 groups of 6 animals each and a 
sub-acute experiment was designed and performed as described in table 1.   
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Table 1 Experimental designing 
 
Groups Treatment Solution 
a
 Administration 
   
Control Sterile saline Daily during 8 days 
Mn 10 mg Mn Cl2/kg Daily during 8 days 
   
Ebselen 15 mg Ebselen/kg Daily during 8 days  
Mn + Ebselen 10mg Mn Cl2/kg +  15mg Ebselen/kg Daily during 8 days 
   
PAS 120 mg PAS/kg Daily during 4 days 
Mn + PAS 10 mg Mn Cl2/kg + 120 mg PAS/kg Daily during 8 days  + the last 
4 days 
 
a 
All treatment solutions were prepared fresh daily and administered according to the 
animals weight. Sterile saline, Mn and the EBS solution were administered by i.p. injection 
(fig. 11). The PAS solution was administrated by s.c. injection (fig. 12). 
 
  
During the experiment body weight was measured, the behavior was observed and 
24h urine was collected, using metabolic cages (fig 13.).  
 
 
 
 
 
 
 
 Fig. 13 - Metabolic Cage. 
Fig. 11- Inraperiteonal injection technique. Fig. 12 - Subcutaneous injection technique.  
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Hereafter, the rats were anesthetized with pentobarbital sodic (60mg/kg) via i.p. and 
before the sacrifice, blood was collected by cardiac puncture (fig. 14) and divided in 
two sterile tubes: one for whole blood analyses (heparinized tube) and another for 
serum, obtained by centrifugation. 
 
 
 
After sacrifice, brain, liver and kidneys were dissected, rinsed with cold 0.9% sterile 
saline, dried out in filter paper, weighted and stored in individual polypropylene 
tubes. All samples were immediately frozen at -80oC. 
Next, the organs removed were used for the determination of several parameters 
using analytical procedures:  
 
 Mn levels were measured by atomic absorption spectrometry in brain and 
blood;  
 GSH was analyzed by high performance liquid chromatography (HPLC);  
 PRL levels were determined by an enzyme immunoassay method 
 MDA was quantified by the thiobarbituric acid assay (TAA) / Dousset 
technique. 
 
 
 
Fig. 14 - Cardiac Puncture technique. 
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8.3. ANALYTICAL METHODS 
 
 
8.3.1. DETERMINATION OF MN IN BRAIN AND BLOOD 
 
Sample preparation – Brain and blood samples were digested prior to GFAAS 
analysis, with an oxidizing acid mixture (65% suprapure nitric acid: 30 % hydrogen 
peroxide). Using a microwave-assisted acid digestion, for each blood sample 90µl 
was added to the Teflon cups while for brain samples 80mg of brain homogenate 
was used and then 2.9ml of the oxidizing mixture was finally added to all of them. 
The cups were sealed, placed inside the respective bombs (Parr Microwave Acid 
Digestion Bombs ®) and subjected to microwave irradiation for 30” (900W). 
The resulting solutions were transferred to 15ml volumetric flasks and 300 µl of a 
0,84mol/L chemical modifier magnesium nitrate (Mg(NO3)2
.6 H2O) solution was 
added to each balloon. Volumes were completed with deionized water. The 
solutions were used for the determination of Mn levels by atomic absorption. 
 
 
Graphite Furnace Atomic Absorption Spectrometry (GFAAS) - A PerkinElmer 
AAnalyst™ 700 atomic absorption spectrometer equipped with an HGA Graphite 
Furnace , a programmable sample dispenser (AS 800 Auto Sampler), and WinLab 
32 for AA software was used to determine Mn concentrations at Laboratório de 
Métodos Instrumentais de Análise (Faculdade de Farmácia da Universidade de 
Lisboa). Samples were measured at least twice and every measurement consisted 
of two separate injections into the graphite furnace. Results were expressed as 
micrograms of Mn per g of brain tissue and micrograms of Mn per milliliter of blood. 
Calibration curves were obtained with standard solutions of 2, 5, 10, 15 and 25 µg/L 
of MnCl2. The limit of quantification determined was 0.05 µg/L. 
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8.3.2. ANALYSES OF GSH IN BRAIN 
 
Sample preparation – Brain tissue was homogenized and samples were weighted 
(approximately 35mg). PBS solution was added, 20 times the weight in volume 
which means that for a 35mg sample it was added 700µL of PBS. Samples were 
macerated and afterwards sonicated (30 cycles; Conditions: Cycle 0.5, Amplitude 
100) and centrifuged for 10’ at 10 000rpm. The supernatant was then collected to 
1ml eppendorfs.  
This last step was followed by a derivatization technique: four standards solutions 
were used to determine the GSH levels, namely GSH 32.5µM, 65µM, 130.1µM and 
GSSG 52.3µM. A mix was made of 100 µl sample/standard + 5 µl of the Internal 
Standard (IS) [Cysteamine 40.6 µM+ N-(2-mercaptopropionyl)-glycine (MPG) 
2500µM)], + 5µl of the reducing agent [dimethylformamide (DMF)/tributylphosphine 
(TBP) (90:10)]. Two derivatizations per sample were made and the second 
derivatization consisted in repeating the last step but without the reducing agent 
(DMF/TBP). The samples were incubated for 30 min at 4 ºC. Next, 50µl of TCA 10% 
2 mM EDTA was added to these mixtures followed by a 10 min centrifugation at 
14000g. 50µL of the resulting supernatant was then transferred to new eppendorfs 
and it was added 10 uL of NaOH 1.55 M + 100 uL of borate buffer 100 mM EDTA 4 
mM pH 9.5 + 50 uL of derivatization reagent, 7-fluorobenzofurazan-4-sulfonic acid 
ammonium salt (SBD-F). Finally, a 60 min incubation at 60 ºC followed by an 
incubation of the eppendorfs on ice during 5 min was performed, and samples were 
analyzed by HPLC. All samples were handled on ice whenever possible and only 
non-metallic utensils were used to prevent oxidation of thiols during sample 
manipulation. 
 
HPLC analyses – GSH levels in brain tissue were measured by HPLC at the Centro 
de Patogénese Molecular, i-Med, Universidade de Lisboa. HPLC was equipped with 
a Supelcosil LC-18-S reverse phase column, a Waters 2475 fluorimeter detector 
and a Waters 2695 separation module. The elution solvent was KH2PO4 0.1 M 
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(13.6 g/L) (pH 2.1) with 5% ACN and the Flow was 1.6 mL/min, isocratic. The run 
time was 20 min. HPLC system was compatible with Water Empower II Software.  
 
8.3.3. DETERMINATION OF PROLACTIN IN SERUM 
 
An enzyme immunoassay (SPIBIO®) was used to quantify PRL in serum. All the kit 
assay procedures were strictly followed to obtain optimal results. 
 
Sample preparation – The samples were thawed on the assay day, vortex and 
centrifuged at 1600g for 20 minutes, to eliminate fibrin. All the seven necessary 
reagents (EIA buffer, Rat Prolactin Standard, Quality Control, Rat Prolactin-AChE 
tracer, Rat Prolactin antiserum, Wash Buffer and Ellman’s Reagent) were prepared 
on the experiment day. Next, the plate was prepared in duplicate and different tips 
were used to pipet the reagents and samples into the wells following once more the 
kit assay procedure. Then the plates were covered with a plastic film and incubated 
for 20h at room temperature. Before reading, the plates were emptied by turn over 
and shaking and each well was washed five times with the wash buffer (300 
µL/well) followed by 200 µL/well of Ellman’s Reagent. Again the plates were 
incubated in the dark (covered with an aluminium sheet) at room temperature and 
placed in an orbital shaker for optimal development. 
 
Plate reader - The plates were read in an Anthos Zenyth 3100 microplate detector 
between 405 and 414 nm (yellow color) at Laboratório de Toxicologia (Faculdade 
de Farmácia da Universidade de Lisboa). The limit of quantification was 1 pg/ml 
 
8.3.4. DETERMINATION OF MALONDIALDEHYDE VALUES IN URINE 
 
The determination of lipoperoxidation products in urine was made by the 
Thiobarbituric Acid Assay (adapted from Dousset et al., 1983) 
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Reagent preparation – The TBA reagent was prepared fresh daily. 200 mg of 
thibarbituric acid were added to 7ml of 2N NaOH and then the pH was adjusted to 
7.4 with 7% perchloric acid. The resulting solution was transferred to a 25 ml 
volumetric balloon and the volume was completed with deionized water. Next, two 
volumes of this solution were added to one volume of 7% perchloric acid. Aliquotes 
of 500µl of urine were pipetted into screw-cap, heat resistant glass tubes, containing 
12,5µl of butilhidroxitoluene (BHT) 0,6% in absolute alcohol. 750µl of fresh prepared 
TBA reagent was then added. The tubes were tightly closed, vortex and placed in a 
boiling bath for ten minutes. After they were cooled down to room temperature and 
700µl of n-butanol added to each tube, they were vortex thoroughly again and 
centrifuged for 20/25min at 3000g. 
 
Spectrophotometer analysis – After centrifugation the organic phase was carefully 
removed into a different tube, and the absorbance was measured at 532nm using a 
Hitachi U-2000 Spectrophotometer at Laboratório de Toxicologia (Faculdade de 
Farmácia da Universidade de Lisboa). 
 
 
8.4. BEHAVIORAL ASSAYS 
 
A review of many studies considering occupational, environmental and childhood 
exposure, reinforced the known neurobehavioral effect of Mn and it was Zoni et al. 
(2007) in a review that suggested that motor function tests should be included in 
future studies to determine any Mn effect. 
Motor activity was assessed on all groups at two different times: just before the 
beginning of the experiment and on the last day of treatment. The order of testing 
was randomized, and the observer was maintained blind to the treatment of each 
animal. All the rats were tested individually in an open field (60 cm x 90 cm) divided 
into six equal squares and surrounded by a 30 cm-high opaque wall. Because 
motor activity can be often affected by many environmental conditions such as 
sound level, cage design, light, temperature, humidity and odors, the records took 
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place in an independent room, at a fixed hour of the day with controlled light and 
sound. At the beginning of each session the open field was cleaned, the animals 
were placed at its centre and the behavior of each rat was observed for 5 min. Two 
behavioral parameters were studied according with Ladefoged evaluation (1994): 
ambulation (number of crossings within 5 min in an open field) and rearing (number 
of times within 5 min where both forelegs were raised from the floor in the same 
open field). 
 
8.5. STATISTICAL ANALYSIS 
 
All the analyses were conducted using SPSS STATISTICS® version 17.0, 2008. All 
the results were tested for parametric assumptions (Kolmogorov-Smirnov and 
Levene’s test) and non-parametric tests proved to be the best approach. For each 
parameter Mann-Whitney tests were used to compare for the significant difference, 
control group with all groups, Mn group with Mn+PAS and Mn+EBS groups. PAS 
group was also compared with Mn+PAS group and EBS with Mn+EBS. Limit for 
statistical significance was set at p<0.05 (significance level of 95%). 
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9. RESULTS 
 
9.1. BODY WEIGHT 
 
Body weight was measured several times along the experiment and it was possible 
to observe a significant loss of weight gain in the Mn treated group comparing to 
control. Looking at Mn plus EBS and Mn plus PAS groups if we compare them with 
control it is shown a significant increase and a non significant decrease in body 
weight gain, respectively. Comparing with the Mn group we can see a significant 
gain of weight for Mn plus EBS and Mn plus PAS groups. There was also a 
significant difference comparing the EBS group with the control and also comparing 
the EBS and PAS treated rats with Mn plus EBS and Mn plus PAS, respectively. 
(Fig. 15) 
 
 
 
 
 
 
 
 
 
 
Fig. 15 - Body Weight. Data represent the mean ± STDV. Control 
was compared with all the groups. Mn+EBS was compared with 
Mn and EBS and Mn+PAS with Mn and PAS by Mann-Whitney 
tests: *, ^, º and # are p < 0.05 versus Control, Mn, PAS and EBS 
respectively. 
Control        Mn           EBS           PAS      Mn+EBS    Mn+PAS 
*^ # 
^º 
* 
* 
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9.2. MN CONCENTRATIONS IN BLOOD 
 
The Mn concentration in blood was measured. Comparing the Mn, Mn plus EBS 
and Mn plus PAS treated animals with the control, all the three groups showed a 
significant difference (p<0.05). When compared to Mn we observed that not only Mn 
plus EBS but also Mn plus PAS had their concentrations significantly reduced. It is 
also shown a significant difference between PAS and Mn plus PAS. (Fig. 16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 – Mn levels in blood. Data represent the mean ± STDV. 
Control was compared with all the groups. Mn+EBS was 
compared with Mn and EBS and Mn+PAS with Mn and PAS by 
Mann-Whitney tests: *, ^, º and # are p < 0.05 versus Control, 
Mn, PAS and EBS respectively. 
 
 
* 
*^ *^º 
 Control        Mn           EBS           PAS       Mn+EBS    Mn+PAS 
In vivo assays to study the interference of chemoprotectors on manganese neurotoxicity 
 
35 
 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
1,80
2,00
(µ
g
 M
n
/g
 t
is
su
e
) 
 
Mn in Brain
*
*^# *^º
*
9.3. MN CONCENTRATIONS IN BRAIN 
 
After the measurement of Mn concentrations in brain we could see a significant 
increase of Mn in the Mn group and in both co-exposed groups (Mn plus EBS and 
Mn plus PAS), comparing to control. On the other hand, when we compare the two 
co-exposed groups with the Mn group we can see a significant decrease (p<0.05) of 
Mn in brain. There was also a significant difference analyzing both EBS and PAS 
with Mn plus EBS and Mn plus PAS group, respectively. (Fig. 17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 – Mn levels in brain. Data represent the mean ± STDV. 
Control was compared with all the groups. Mn+EBS was compared 
with Mn and EBS and Mn+PAS with Mn and PAS by Mann-Whitney 
tests: *, ^, º and # are p < 0.05 versus Control, Mn, PAS and EBS 
respectively. 
 
Control         Mn           EBS            PAS       Mn+EBS    Mn+PAS 
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9.4. GSH LEVELS IN THE BRAIN 
 
The amount of GSH in its reduced state was measured. Observing the results, GSH 
was significantly reduced in the Mn group compared to control (p<0.05). Concerning 
Mn plus EBS and Mn plus PAS groups, they were significantly different from the Mn 
group (p<0.05) and similar to control.  It was also possible to see a major significant 
difference when we compare the EBS group with the control and Mn plus EBS as 
well as a decrease in the brain GSH content looking at the PAS and Mn plus PAS 
group (Fig. 18). 
 
 
 
 
Fig. 18 – GSH levels in brain. Data represent the mean ± STDV. Control 
was compared with all the groups. Mn+EBS was compared with Mn 
and EBS and Mn+PAS with Mn and PAS by Mann-Whitney tests: *, ^, º 
and # are p < 0.05 versus Control, Mn, PAS and EBS respectively. 
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9.5. PROLACTIN IN SERUM 
 
PRL levels were quantified in serum and it was observed a significant increase in 
the Mn and Mn plus EBS treated animals when compared to the control (p<0.05). 
Furthermore, it was observed that the amount of PRL was significantly decreased in 
the Mn plus EBS and Mn plus PAS groups if we compare with Mn (p<0.05). It is 
also shown, comparing the control with Mn plus PAS that no difference was found 
(Fig. 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 – Prolactin levels in serum. Data represent the mean ± STDV. 
Control was compared with all the groups. Mn+EBS was compared 
with Mn and EBS and Mn+PAS with Mn and PAS by Mann-Whitney 
tests: *, ^, º and # are p < 0.05 versus Control, Mn, PAS and EBS 
respectively. 
Control         Mn           EBS           PAS       Mn+EBS    Mn+PAS 
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9.6. MDA LEVELS IN URINE 
 
MDA levels were measured in 24h urine of the rats before the sacrifice. When we 
compare the Mn group with the control we can see an increase of MDA in the first 
group, but that difference was not significant. Concerning the co-exposed groups, it 
was not observed a significant difference between these groups and Mn or control 
groups. Only the PAS treated animals had significant increased MDA values when 
compared to control and also a significant difference when compared to Mn plus 
PAS (Fig. 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 – MDA levels in urine. Data represent the mean ± STDV. 
Control was compared with all the groups. Mn+EBS was compared 
with Mn and EBS and Mn+PAS with Mn and PAS by Mann-Whitney 
tests: *, ^, º and # are p < 0.05 versus Control, Mn, PAS and EBS 
respectively. 
Control        Mn            EBS          PAS      Mn+EBS    Mn+PAS 
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9.7. BEHAVIORAL ASSAYS 
 
Behavioral parameters were studied for all the groups which includes control, Mn, 
EBS, PAS, Mn plus EBS and Mn plus PAS.  Two parameters (horizontal activity and 
vertical activity) were analyzed at two different times (before the beginning of the 
experiment and before the animals sacrifice). Observing the results, we can say that 
MnCl2 treated rats had a highly significant decrease in spontaneous activity, for both 
ambulation and rearing, compared to control (Fig. 21 and 22). Comparing the 
control with Mn plus PAS and Mn plus EBS, for ambulation activity, we can see that 
there are no significant differences (Fig. 21). On the other hand, and looking at the 
vertical activity, Mn plus PAS is the group with no significant decrease while Mn 
plus EBS shows a reduction in activity (P<0.05) (Fig. 22). Comparing the Mn group 
with the co-exposed groups we can say that Mn plus EBS treated rats had a 
significant increase in spontaneous activity (P<0.05), for both ambulation and 
rearing while Mn plus PAS had it only for rearing (Fig. 22). 
 
 
 
 
 
 
 
 
 
Fig. 21 – Ambulation counts. Data represent the mean ± STDV. 
Control was compared with all the groups. Mn+EBS was compared 
with Mn and EBS and Mn+PAS with Mn and PAS by Mann-Whitney 
tests: *, ^, º and # are p < 0.05 versus Control, Mn, PAS and EBS 
respectively. 
* 
^ 
Control         Mn           EBS           PAS       Mn+EBS    Mn+PAS 
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Fig. 22 – Rearing counts. Data represent the mean ± STDV. Control 
was compared with all the groups. Mn+EBS was compared with Mn 
and EBS and Mn+PAS with Mn and PAS by Mann-Whitney tests: *, ^, 
º and # are p < 0.05 versus Control, Mn, PAS and EBS respectively. 
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10. DISCUSSION 
 
As stated before, Mn is, in small amounts, an essential microelement in the human 
diet and its deficiency can lead to serious health problems. However, at excessive 
exposure, it has been proved to be toxic and an accumulation of Mn in the 
organism can have repercussions on a number of organ systems, especially in the 
central nervous system which leads to neurodegerative alterations, causing a 
Parkinson-like syndrome [148], motor neuron disease [149] and disturbed 
psychomotor development [150]. All Mn related symptoms have been studied for a 
long time in hundreds of human cases all over the world [151], [152], and even 
nowadays, more than ever, the study of the neurotoxic effects of Mn holds special 
clinical relevance in occupational, clinical and environmental toxicology [153]. 
Knowing the difficulties of preventing and diagnosing early Mn exposure and the 
very little success in treating chronic states of the disease with drugs like 
Levodopa Trihexphenidyl, Bromocriptine, and Amantidine, used in the typical drug 
treatment, this research was undertaken with the objective of studying the 
interference of two potential antagonists, namely PAS and EBS, on Mn 
neurotoxicity. 
Therefore, a sub-acute in vivo assay was performed using Wistar Rats exposed 
not only to repeated doses of MnCl2 but also co-administrated with PAS and EBS.  
 
The selection of PAS was based on its chemical structure which provide promising 
chelating properties for metals and its probable capacity of forming stable Mn2+ 
complexes that can be rapidly oxidized to an even more stable Mn3+ complex and 
ultimately remove both these Mn ions from the intracellular matrix under 
physiological conditions. In fact, in a 1975 study it was shown that PAS is capable 
of removing Mn from the liver and testis in Mn-exposed rats [118] and more 
recently, in high doses, it could significantly reduce Mn levels not only in organs 
such as the liver, heart, spleen and pancreas but also in brain structures like the 
striatum, thalamus, choroid plexus, hippocampus and frontal cortex [49]. 
Knowing that one of the mechanisms of Mn-induced toxicity is through oxidative 
stress, the selection of EBS was based on its known antioxidant properties. EBS 
has the ability to reach the cells as a result of its binding to the intracellular thiol 
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groups such as GSH [154] and it inhibits the peroxidation of membrane 
phospholipids [155], inhibits enzymes involved in inflammation such as 
lipoxygenases [156], blocks the production of superoxide anions by activated 
leukocytes [157], inhibits inducible NOs [112] and exhibits a sustained defense line 
effect against ONOO- [158]. To the best of our knowledge, there are no studies 
demonstrating the effects of EBS in Mn exposed rats but there is one study about 
EBS inhibition of Fe uptake barely suggesting that EBS did not inhibit 54Mn 
uptake in cells [159]. 
With the intention of evaluate the interference of these 2 chemicals on Mn 
toxicokinetics and toxicodynamics, several indicators were used.  
 
During the in vivo experiment, the body weight was assessed at different times 
and it was observed a significant deficit in body weight gain in the Mn treated 
group (p<0.05) (Fig. 15). Similar results have been described in other studies 
[160], [161]. Comparing the body weight gain of the co-treated animals with the 
ones exposed only to Mn, it was possible to observe a remarkable increase in 
weight (p<0.05) which leads us to say that both PAS and EBS, somehow, had a 
significant intervention in the already expected loss of weight in the Mn treated 
rats. The use of PAS in tuberculosis treatment is known to be associated with a 
gain in appetite and subsequent increase in weight [162] while organic selenium 
compounds seem also to lead to an increment of body weight [163], [164], which 
would explain our EBS results. Although both chemicals seem to had, directly or 
indirectly, an advantageous action against the reduction of weight gain, further 
studies are necessary to evaluate the exact interaction mechanism.   
Even if nowadays there aren’t strong correlations between Mn toxicity and 
biomarkers of exposure, we selected Mn blood and brain levels to evaluate the 
internal dose of Mn. In our study, the levels of Mn in blood are significantly higher 
(p<0.05) for the Mn, Mn plus PAS and Mn plus EBS groups when compared to 
control (Fig. 16). However, it is noteworthy that, when comparing the Mn exposed 
rats with the co-treated groups there is also a significant difference between them. 
Analyzing these results we can say that Mn in blood demonstrated to be a useful 
biomarker of exposure since not only there was significant difference between the 
control and Mn group (p<0.05) but also that difference seemed to be huge 
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because the Mn blood levels in both Mn plus PAS and Mn plus EBS groups 
showed significant different medium values (p<0.05) in between the control and 
Mn, compared to them. The observed difference between the control and the Mn 
exposed animals is consistent with others studies suggesting that blood Mn is 
associated with exposure and adverse neurologic effects [26], [165-171]. Despite 
the comparison between the co-treated groups and the control had showed a 
great increase in the blood Mn, this increase was substantial lower when 
compared to the Mn group. It is possibly that PAS molecules were able to complex 
Mn in the blood and likely facilitate the movement of Mn from cell compartments 
such that Mn ions can be made available to be transported to the extracellular fluid 
and subsequently eliminated from the body [49], decreasing Mn levels in blood. In 
the case of EBS, we suggest that its known antioxidant and free radicals 
scavenging properties may somehow inhibit the oxidation of Mn2+ to Mn3+ and 
since Mn2+ is used for essential organism function it may be rapidly absorbed to 
intracellular compartments and consequently, leave the blood stream. Moreover, 
there is a study indicating that Mn3+ exposures produce significant higher blood 
Mn levels than equimolar exposures to Mn2+ [172], which helps to solidify our 
hypothesis and also explain our results in the Mn plus EBS group.  
Nevertheless, regardless of these results, Mn has a half-life in blood of t1/2 < 2h 
[173] and this relatively brief half-life make blood Mn more indicative of recent 
exposure, rather than serving as a marker of long-term or chronic exposure. 
Furthermore, some studies suggest that blood Mn levels may not even be reliable 
indicators to measure recent exposure [174] which goes against several studies 
results, including this experiment. 
 
Several pharmacokinetic studies with exposure to Mn have demonstrated that Mn 
readily accumulates in the brain. Under normal conditions it can go across 
different brain regions such as the substantia nigra, striatum, hippocampus and 
frontal cortex [175.] However, research studies have shown that this accumulation 
can be conditioned by some important elements: dosage [93], route of 
administration [176], exposure to different Mn ions [172], animal species used in 
the experiment [177] and a slow Mn elimination from the brain compared with 
other organs. 
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Looking at our results, there is an evident and significant different (p<0.05), Mn 
accumulation in brain in the Mn exposed rats, when compared not only to control 
but also to the co-treated groups (Fig. 17). These results suggest that both PAS 
and EBS had the ability to diminish Mn concentrations in the brain following 
exposure. Regarding the PAS results, the reduction observed in Mn brain levels is 
consistent with the results obtained by other authors and can be explained by the 
PAS chelating capacity and also by a optimal given dose of PAS for treatment 
which may be able to mobilize and remove Mn from its common intracellular 
deposit sites [49]. Moreover, its unique ability of passing across the blood–CSF 
barrier makes it possible for drug molecules to gain access to Mn ions that are 
deeply bound to brain targeted cells. EBS, on the other hand, certainly has a 
different approach respecting the capacity of lowering Mn in brain. Taking into 
account that EBS is a potential DMT-1 transport inhibitor, preventing Fe uptake in 
cells [159] we suggest that the obtained Mn brain levels may be also due to the 
inhibition of the Mn transport into the brain. Although, the antioxidant properties of 
EBS may influence the activity of specific factors responsible for the modulation of 
Mn intracellular levels, further investigations to study which factors and the exact 
mechanism are necessary. 
Even though it was observed a significant decrease (p<0.05) of brain Mn in the Mn 
plus PAS and Mn plus EBS groups, these two groups still show a significant 
increase (p<0.05) of brain Mn when compared to control. An explanation for these 
results lies on the fact that neither the dosage administration for PAS nor for EBS 
may have been sufficient to decrease even more the Mn brain levels. Better 
results may be observed with higher doses and/or a longer/constant 
administration. 
 
In our experiment we also intended to investigate the potential change in the 
metabolism/normal function of body organs which may lead to adverse health 
effects as a consequence of Mn toxicity. These changes, if common and frequent, 
are usually called biomarkers of effect and if well correlated and validated, may 
help us to assess recent and/or long-term Mn exposures and the consequent 
effects. Since oxidative stress is one of the probable mechanisms of Mn-induced 
neurotoxicity, biomarkers of oxidative stress, namely GSH and MDA, were 
In vivo assays to study the interference of chemoprotectors on manganese neurotoxicity 
 
45 
 
investigated. Several studies show that the production of ROS can increase and 
be provoked by the presence of Mn [106], [178] with depletion of antioxidant 
defense mechanisms [179]. GSH, a ubiquitous antioxidant, protects the cells 
against oxidative stress. Thus, studying oscillations on levels of this antioxidant 
can be a indirect measure of oxidative stress. There is evidence that GSH plays 
an important role in the detoxication of ROS in brain [180-183] and so GSH brain 
variations are associated with the loss of neurons during the progression of 
neurodegenerative diseases [184-187]. 
In our experiment GSH brain levels showed a significant decrease in the Mn group 
compared to control (Fig. 18). Identical results showing a GSH decrease in Mn 
exposed rats also has been observed in other in vivo [188], [102] and in vitro [189], 
[190] studies. Comparing the control and Mn groups with the co-treated animals 
we can say that both PAS and EBS had a remarkable protective function against 
the depletion of GSH brain levels because we cannot see a significant reduction 
comparing to control but, on the other hand, when compared to the Mn exposed 
animals we observe a significant difference (p<0,05) between them. This PAS 
results can be explained by its already referred chelating properties. By removing 
Mn from the cellular compartments it avoided the Mn toxicity and the decrease in 
GSH levels. The EBS results are consistent with other studies that also suggest an 
EBS interaction against the reduction of GSH levels [191], [192]. Its well studied 
mechanism of action indicates that it can act as GPx mimic in reducing H2O2 and 
lipid hydroperoxides [193], [194], scavenge the highly reactive species ONOO- 
[158], and inactivate free radical generating enzymes [113], [195], [114], thus 
explaining the increased GSH levels, compared to the Mn group, in the Mn plus 
EBS group.  
 
Another potential mechanism by which Mn may induce its toxicity is through 
dopamine oxidation which is supported by evidence showing that chronic 
exposure to Mn leads to selective dopaminergic dysfunction and neuronal loss 
[196]. Since PRL production and secretion are controlled by the hypophyseal-
pituitary endocrine system, with dopamine functioning as a supressor of PRL 
levels [197], [198], and Mn is known to affect the dopaminergic pathway, reducing 
dopamine levels in brain [199] we expected to observe an increase in the quantity 
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of serum PRL in the Mn exposed rats and probably smaller values in the co-
treated animals. In this case the increase in PRL levels would be very useful to 
assess not only a potential exposure to Mn but also its neurotoxic effects, 
functioning as a biomarker of effect. Several reports show that PRL levels can be 
used as a biological index of Mn exposure in humans [140] while others still 
support negative relationships between Mn and PRL [26], [143]. Observing the 
results obtained in our experiment we found a significant increase (p<0.05) of PRL 
levels in the Mn group when compared to control (Fig. 19). Furthermore, the Mn 
plus PAS and Mn plus EBS groups showed a significant decrease (p<0,05) in PRL 
levels when compared to the Mn exposed animals. These are remarkable results 
since not only the amount of PRL released showed to be a useful biomarker of Mn 
exposure but also the chemicals used to interfere with Mn toxicity, proved to be 
protective. Once more, we suggest that PAS ability to decrease the Mn quantity 
present in the body was indirectly responsible for the improvement of dopamine 
release and consequently decrease of PRL. Confirming our results it has been 
reported, in a study conducted in a cell model, the positive effect of PAS in the 
dopaminergic system affected by Mn [200]. Respecting EBS we suggest that its 
already investigated antioxidant properties which protect against neurotoxicity may 
prevent the Mn suppression of the inhibitory feedback control of dopamine, 
decreasing dopamine oxidation, but a deep examination on how this mechanism 
works would give a new insight on EBS interference in the affected dopaminergic 
system. In addition, and despite significantly different from the Mn group, it was 
observed that the EBS co-exposed rats showed a significant increase (p<0.05) 
when compared to control. Again, we suggest that other doses or a longer period 
should be evaluated.  
 
In our work we further investigated another proposed biomarker of oxidative 
stress, malondialdehyde (MDA), one of the most frequently used indicators of lipid 
peroxidation. ROS degrade polyunsaturated lipids, forming MDA [201] which is 
reactive and potentially mutagenic [202]. A 1996 study showed a positive 
correlation between the concentrations of MDA in Mn exposed workers and the 
Mn level in plasma, suggesting that MDA can be used as an index of lipid 
peroxidation induced by Mn exposure [203]. To further determine if MDA can be 
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truly used as an indicator of Mn toxicity we measured the levels of MDA excreted 
in urine. Looking at our results and according with what we expected, MDA 
increased in Mn exposed rats, although the difference was not significant (p>0.05) 
(Fig. 20). In addition, no significant differences between the other groups can be 
observed. When compared to others indicators of lipid peroxidation, such as 
isoprostanes, which are regarded as the most accurate compounds to measure 
oxidative damage in vivo [208], [209], MDA seems to have little specificity as an 
indicator of lipid peroxidation and consequently as an indicator of Mn exposure. 
 
An observation of the animals’ behavior was evaluated since the high sensitivity 
and integration of motor, sensory and motivational functions make behavioral tests 
an important tool to use as a probable indicator of Mn neurotoxicity and also may 
ultimately reflect all the mechanisms and chemical changes at the cellular level. 
After the administration of all eight doses, the MnCl2 treated rats had a highly 
significant decrease (p<0.05) in spontaneous activity, for both ambulation and 
rearing when compared to control (Fig. 21 and 22). This is in line with previous 
studies where rats exposed to MnCl2 showed a decrease spontaneous activity in 
open field activity [160], [204]. Since the effect of Mn depends on the central 
dopaminergic-glutamatergic interactions [205] while the mesolimbic and 
mesocortical dopaminergic neuronal transmission, with the involvement of motor 
control centers such as the globus pallidus, substantia nigra, and deep cerebellar 
nuclei is responsible for locomotor activity [206], [207], the observed decrease in 
motor activity indicates that Mn has affected dopaminergic control. Comparing the 
Mn group with Mn plus EBS and Mn plus PAS we observed a general significant 
increase in spontaneous activity (P<0.05) with the exception for ambulation in the 
Mn plus PAS group (Fig. 21). Although, we observed a moderate increase of the 
rearing activity for this group which indicates that with an additional continuous 
dose administration we probably would observe a similar significant result. These 
results may be explained by the chelating properties of PAS as well as the 
antioxidant properties of EBS which may avoid the oxidative process of 
catecholamines, in such a way that the sensitivity of the post synaptic dopamine 
receptors could increase, explaining a return of locomotor activity.  
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Finally, the correlation between the Mn levels in brain with the PRL levels in serum 
and the behavior outcomes was performed. We observed that the Mn levels in 
brain but showed a good correlation with the behavior effects and a remarkable 
correlation with the PRL serum levels (r2=0.87 and r2=0.98, respectively), proving 
to be a sensitive biomarker of Mn neurotoxicity. 
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11. CONCLUSIONS 
       
Experimental in vivo studies with Wistar rats repeatedly exposed to Mn, Mn+EBS 
and Mn+PAS allow us to conclude: 
 
• In Mn exposed rats a significant increase in brain and blood Mn levels was 
observed as compared with control. In addition, the increase of brain Mn 
levels was much higher than in blood. Thus, our results indicate these 
biomarkers as good indicators of Mn exposure  
 
• In rats exposed to Mn, serum PRL levels and brain GSH levels are 
significantly different from control and showed to be good predictive 
biomarkers of Mn neurotoxicity. 
 
• MDA levels in urine of rats exposed to Mn showed no significant increase in 
lipid peroxidation as compared with control.  According with our results, 
MDA is not a good biomarker of Mn toxic effect. 
 
• PAS and EBS show protective/antagonist properties against Mn 
neurotoxicity as rats co-exposed to Mn and each one of these two 
chemoprotectors significantly decrease Mn accumulation in brain, as well 
as the subsequent neurotoxicity observed in the behavioral assays. 
 
• Mn levels in brain showed a good correlation (r2=0.98) with PRL serum 
levels and the behavioral effects (r2=0.87) and so are reliable and sensitive 
biomarkers that reflect the Mn exposures and also are predictive of its 
neurotoxicity. 
 
• Finally, considering the changes observed on toxicokinetics and 
toxicodynamics of Mn (biomarkers of exposure and effect) in rats co-
exposed to Mn+PAS and Mn+EBS, we suggest that these two 
chemoprotectors may be of great use in the protection/antagonism of Mn 
exposures.  
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• Future studies are needed and already planned to confirm our results using 
other doses and times of exposure in order to clarify the mechanisms 
underlying these protective effects on  Mn neurotoxicity     
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